FIELD: biotechnology; immunology;virology.
SUBSTANCE: following is described: a hybrid gene encoding a recombinant antigen consisting of the RBD receptor of the surface protein S of the SARS-CoV-2 coronavirus, the S14P5 and S21P2 epitopes, the Fc fragment of the IgG1 immunoglobulin, represented as the amino acid sequence of SEQ ID NO: 1. An expression construct is also described in the P-Pharma-Zeo vector represented by SEQ ID NO: 4 containing the nucleotide sequence of SEQ ID NO: 2, consisting of the hybrid gene described above and the sequence of SEQ ID NO: 3 encoding the IL2 leader peptide. A CHO-HP cell line transfected with the expression construct described above to produce the recombinant RBD/S21/S14-Fc antigen is described. A method for obtaining a recombinant RBD/S21/S14-Fc antigen is presented, involving the cultivation of the above-mentioned CHO-HP cell line, under conditions of feeding 4 mM L-alanine-L-glutamine and an anti-cell aggregation reagent, followed by the selection of the culture fluid, its clarification, and filtration, chromatographic purification of the target recombinant antigen, including affinity chromatography, HA sorbent chromatography, hydrophobic and gel permeation chromatography, followed by sterilizing filtration. The recombinant antigen RBD/S21/S14-Fc obtained by the above method is presented, which stimulates the immune response in the body to coronavirus infection. A vaccine composition for the prevention of coronavirus infection is presented, containing the above recombinant antigen and a corpuscular adjuvant based on natural betulin in a buffer solution. A method for the prevention of coronavirus infection is disclosed, which involves immunization of requiring protection patients against coronavirus infection with the above vaccine composition.
EFFECT: invention expands the arsenal of means to combat SARS-CoV-2.
7 cl, 10 dwg, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
| PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
| ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
